# Arcadia Biosciences, Inc. (RKDA) · Edgar & Edgarette company card

> Arcadia Biosciences (RKDA) saw revenue fall 3.7% in FY2025 to $5 million, operating margin -51.5% against a 16.8% median for crude petroleum & natural gas, equity 63.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1469443 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/RKDA) · [JSON](https://www.pops4.com/boards/company/RKDA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $5M |
| Revenue growth, 1 year | -3.7% |
| Revenue growth per year | -8.0% |
| Operating margin | -51.5% (prior year -72.3%) |
| Net margin | -48.1% |
| Operating cash flow | −$5M |
| Capital spending | $0 |
| Free cash flow | −$5M |
| Cash | $259,000 |
| Long-term debt | — |
| Total assets | $7M |
| Total equity | $4M |
| Equity ÷ assets | 63.2% |
| Return on equity | -56.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -136.5 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed auditor change in the last 12 months; operating cash flow was negative; operating loss: a margin of -51.5% in FY2025; revenue is hard to predict: its 80% range is ±49%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $4.9M (FY2025). Experience: revenue down 3.7% on the year, down 8.0% a year over 4 years; operating margin -51.5%, up from -72.3%. Soundness: equity 63.2% of assets, return on equity -56.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.5M and $7.5M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.4M to $8.1M. A statistical range, not company guidance. Against peers (45 filers, $50M+ revenue, crude petroleum & natural gas): operating margin -51.5% against a 16.8% median; growth -3.7% against 7.8%.

Range logged 2026-09-24, receipt f9325af246d7052e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-09-04 ([filing](https://www.sec.gov/Archives/edgar/data/1469443/000119312526383642/0001193125-26-383642-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-04-03 ([filing](https://www.sec.gov/Archives/edgar/data/1469443/000119312526142030/0001193125-26-142030-index.htm))
- Item 5.02 Director or officer change: 3, latest 2026-09-15 ([filing](https://www.sec.gov/Archives/edgar/data/1469443/000119312526391780/0001193125-26-391780-index.htm))

## Recent filings

- 8-K · filed 2026-09-15 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1469443/000119312526391780/0001193125-26-391780-index.htm)
- 8-K · filed 2026-09-04 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1469443/000119312526383642/0001193125-26-383642-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1469443/000119312526349205/0001193125-26-349205-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1469443/000119312526349180/0001193125-26-349180-index.htm)
- DEF 14A · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1469443/000119312526342437/0001193125-26-342437-index.htm)
- 8-K · filed 2026-08-10 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1469443/000119312526340664/0001193125-26-340664-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001469443.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1469443

## Cite

POPS4, Edgar & Edgarette: Arcadia Biosciences, Inc. (RKDA) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/RKDA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.